AbbVie Raises 2026 Outlook to $14.28, Triggers $18M Oncology Milestone
AbbVie posted Q1 adjusted EPS of $2.65 with $15B revenue, topping forecasts and raising its 2026 outlook to $14.28 per share. The company triggered an $18M preclinical oncology milestone payment under its EvolveImmune collaboration and saw immunology sales hit $7.29B led by Skyrizi.
1. Q1 Financial Performance
AbbVie delivered Q1 adjusted EPS of $2.65 and revenue of $15.0B, each exceeding consensus estimates. Strong market share gains in immunology and neuroscience underpinned the beat, with immunology sales reaching $7.29B led by Skyrizi’s leadership in psoriatic disease.
2. Upgraded 2026 Guidance
Following the better-than-expected quarter, management increased its full-year adjusted EPS outlook to $14.28 per share, up 12 cents from prior guidance. The revision reflects confidence in newer growth drivers offsetting Humira declines.
3. Oncology Collaboration Milestone
AbbVie achieved a preclinical milestone in its EvolveImmune Therapeutics partnership, nominating a solid tumor development candidate and triggering an $18M milestone payment. This advancement underscores progress in AbbVie’s oncology pipeline and collaboration strategy.